

## Original Article

# Association between plasma homocysteine status and hypothyroidism: a meta-analysis

Yande Zhou<sup>1</sup>, Yufang Chen<sup>1</sup>, Xueqin Cao<sup>1</sup>, Chunfeng Liu<sup>2,3</sup>, Ying Xie<sup>1</sup>

<sup>1</sup>Department of Endocrinology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China; <sup>2</sup>Department of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China; <sup>3</sup>Institute of Neuroscience, Soochow University, Suzhou 215123, China

Received August 30, 2014; Accepted October 23, 2014; Epub November 15, 2014; Published November 30, 2014

**Abstract:** Purpose: To figure out plasma homocysteine (Hcy) status in patients with subclinical hypothyroidism (SH) and overt hypothyroidism (OH) compared with healthy subjects, and the effect of levothyroxine (L-T4) on plasma homocysteine status in patients with hypothyroidism. Methods: PubMed Web of Science, and The Cochrane Library were used to identify eligible studies. The Newcastle-Ottawa Quality Assessment Scale was used to assess the quality of selected studies. All analyses were performed using the STATA, version 12 software. Results: Our meta-analysis indicated that plasma Hcy concentrations elevated in OH patients without L-T4 treatment compared with healthy subjects. However, this elevation was not observed in the comparison between patients with SH without L-T4 treatment and healthy subjects. Moreover, plasma Hcy levels were found to be higher in patients with OH without L-T4 treatment than in patients with SH without L-T4 treatment. Finally, plasma Hcy concentrations decreased after L-T4 treatment in patients with SH or OH. Conclusions: Plasma Hcy status is associated with the severity of hypothyroidism and L-T4 treatment is helpful for patients with hypothyroidism to reduce the plasma Hcy levels.

**Keywords:** Homocysteine, subclinical hypothyroidism, overt hypothyroidism, levothyroxine, meta-analysis

## Introduction

Hypothyroidism is divided into two types, subclinical hypothyroidism (SH) and overt hypothyroidism (OH), according to the decrease extent of thyroid function. SH is a condition defined as a persistently raised serum thyroid stimulating hormone (TSH) level in the presence of normal free thyroxine (fT4) [1]. Subclinical thyroid failure is often asymptomatic; 30% patients with SH may have symptoms indicating the deficiency of thyroid hormone [2]. Recently, SH has been reported to be closely associated with atherosclerosis and myocardial infarction in elderly women [3]. OH, defined by high TSH levels with low levels of fT4 and/or free triiodothyronine (fT3), is a risk factor for cardiovascular diseases, especially coronary heart diseases [4].

Increasing attention is paid to the risk of cardiovascular diseases in patients with hypothyroidism recently. Homocysteine (Hcy), a sulfhydryl-containing amino acid synthesized during the conversion of methionine to cysteine [5], has been identified as an independently risk factor

for the progression of vascular diseases [6]. The association between homocysteine and hypothyroidism has been demonstrated in several studies, however, the conclusion is controversial [7-9]. As the major treatment of hypothyroidism, levothyroxine (L-T4) replacement has been used for a long time. The effect of L-T4 treatment on plasma homocysteine status in patients with hypothyroidism has not yet reached a consensus [10-12].

Considering all those conflicting studies, meta-analysis may be an appropriate way to summarize available data to provide more strong evidences than the individual study. This meta-analysis was to elucidate plasma Hcy levels in patients with hypothyroidism, and to evaluate the effect of L-T4 therapy on plasma Hcy levels in patients with hypothyroidism.

## Materials and methods

### Search strategy


All the studies that investigated the association between plasma Hcy status and hypothyroid-

# Homocysteine and hypothyroidism

**Table 1.** Characteristics of studies included in this meta-analysis

Study	Year	Country	Control			Case 1			Case 2			Case 3			Case 4			Quality score
			N (F/M)	Age (Y)	Hcy (μM)	N (F/M)	Age (Y)	Hcy (μM)	N (F/M)	Age (Y)	Hcy (μM)	N (F/M)	Age (Y)	Hcy (μM)	N (F/M)	Age (Y)	Hcy (μM)	
Bičíková et al	2001	Czech	No	No	No	No	No	No	No	No	No	14 (12/2)	42±10	15.6±3.6	14 (12/2)	42±10	9.9±1.6	5
Deicher et al	2002	Austria	No	No	No	37 (31/6)	50±18	9.9±2.9	37 (31/6)	50±18	9.6±3.5	No	No	No	No	No	No	5
Bičíková et al	2002	Czech	No	No	No	No	No	No	No	No	No	16 (16/0)	35±8.82	19.2±3.2	16 (16/0)	35±8.82	10.6±2.9	5
Christ-Crain et al	2003	Switzerland	40	54.1±9.2	11.3±2.8	63	57.5±9.8	11.0±2.7	31	No	11.1±3.4	61	55.7±11.7	14.4±9.1	No	No	No	6
Atabek et al	2003	Turkey	19	15±1.8	6.6±1.8	19	14.9±1.9	6.7±1.8	No	No	No	No	No	No	No	No	No	5
Luboshitzky et al	2004	Israel	19 (19/0)	51.7±10.1	9.8±2.6	44 (44/0)	51.6±9.7	9.1±2.4	No	No	No	10 (10/0)	50.1±8.8	13.0±7.9	No	No	No	6
Pe'rez et al	2004	Spain	No	No	No	42 (36/6)	51.7±15	9.5±2.93	42 (36/6)	51.7±15	9.4±3.7	No	No	No	No	No	No	6
Ozcan et al	2005	Turkey	33	41.8±10.2	9.39±2.45	84	41.6±12.4	9.91±2.30	84	41.6±12.4	9.34±2.19	No	No	No	No	No	No	5
Beyhan et al	2006	Turkey	No	No	No	75 (50/25)	42.4±13.1	10±2.5	75 (50/25)	42.4±13.1	9.6±2.5	No	No	No	No	No	No	6
Cakal et al	2007	Turkey	11	39.9±12.5	7.9±0.6	15	41.4±14.1	9.2±3.3	15	41.4±14.1	7.8±2.1	20	41.3±11.1	10.3±3.4	20	41.3±11.1	7.7±2.3	6
Turhan et al	2008	Turkey	50 (47/3)	38.2±10.7	9.6±3.1	53 (47/6)	40.8±12.1	10.3±3.4	No	No	No	No	No	No	No	No	No	6
Erdal et al	2008	Turkey	63 (55/8)	39.43±13.02	9.71±6.90	60 (55/5)	42.28±12.65	9.92±2.22	60 (55/5)	42.28±12.65	9.36±1.90	No	No	No	No	No	No	5
Adrees et al	2009	Ireland	56 (56/0)	47±8	7.8±2.1	56 (56/0)	50±9	10.4±3.6	52 (52/0)	52±10	9.1±2.0	No	No	No	No	No	No	6
Ma et al	2012	China	35 (20/15)	43±12	10.37±3.77	No	No	No	No	No	No	35 (25/10)	43±11	15.78±6.97	35 (25/10)	43±11	12.39±5.67	6
Bamashmoss et al	2013	Yemen	20 (18/2)	29.75±6.15	11.48±3.03	No	No	No	No	No	No	30 (27/3)	37.43±6.92	24.45±5.50	No	No	No	6
Kutluturk et al	2013	Turkey	No	No	No	No	No	No	No	No	No	54 (47/7)	20-75	9.67±5.24	54 (47/7)	20-75	8.16±3.38	6
Anagnostis et al	2014	Greece	No	No	No	32 (30/2)	52.1±13.9	11.29±4.45	32 (30/2)	52.1±13.9	11.94±10.28	No	No	No	No	No	No	6

No = undescribed, Control = healthy people, Case 1 = subclinical hypothyroidism without L-T4 treatment, Case 2 = subclinical hypothyroidism after L-T4 treatment, Case 3 = overt hypothyroidism without L-T4 treatment, Case 4 = overt hypothyroidism after L-T4 treatment, Hcy = homocysteine mean ± SD (μM).



**Figure 1.** Search strategy for meta-analysis.

ism with/without L-T4 replacement were considered in this meta-analysis. A comprehensive literature search was performed for original articles published up from January 1990 to July, 2014 using PubMed, Web of Science databases and The Cochrane Library. The search was restricted to articles in English. As a search criterion, we used the following terms: “hypothyroidism”, “subclinical hypothyroidism”, “overt hypothyroidism”, “homocysteine”, “Hcy”, “levothyroxine”, “L-Thyroxine”, “L-T4” and “thyroid hormone”. References of retrieved articles were also reviewed in case of omitting additional published studies not included in PubMed, Web of Science databases and The Cochrane Library.

#### Study selection

First screening was based on titles and abstracts of retrieved articles, any article lacking the information regarding plasma Hcy status in patients with hypothyroidism was rejected. Editorials, abstracts, review articles and *in vitro* studies were also excluded. Next, second screening was based on the full texts of interested articles. Studies were considered eligible if they met the following criteria: 1) cross-sectional, case-control, prospective or cohort

study; 2) controlled design studies, plasma Hcy levels in patients with SH or OH compared with healthy subjects; 3) effect of L-T4 treatment on patients with SH or OH; 4) data of interest (plasma Hcy concentration) presented as continuous (mean value  $\pm$  SD); 5) mean duration of L-T4 treatment: at least 2 months.

#### Quality scale

The Newcastle-Ottawa Quality Assessment Scale was used here to assess the quality of enrolled studies. The quality scores of included studies ranged from 5 to 6 (low quality: 1-3, median quality: 4-6, high quality: 7-9). As showed in **Table 1**.

#### Data extraction

The data of interest were extracted by two investigators from each article and another senior reviewer checked all items for completeness and accuracy. Information was recorded as follows: first author's surname, publication year, subjects' country, total number of participant subjects, mean ages of controls and cases, plasma Hcy levels in all groups.


#### Statistical analyses

Standard mean deviation (SMD) was used as effect measure to assess the differences in plasma Hcy concentrations among controls and cases. Heterogeneity of SMDs was quantified using I-square ( $I^2$ ) test.  $I^2 > 50\%$  was considered as significant heterogeneity [13]. If there was no heterogeneity, SMDs were calculated using fixed-effects model. If not, random-effects model was applied. Potential publication bias was assessed by Begg's and Egger's test. All analyses were performed using STATA version 12.0 (Stata Corp, College Station, TX, USA).


## Results

#### Literature search

We initially obtained 101 studies from PubMed, Web of Science databases and The Cochrane Library. After 37 duplicated studies removed, 21 studies were then excluded by reviewing titles and abstracts, mainly because they were editorials, reviews or irrelevant to topics. Then



**Figure 2.** Comparison of plasma homocysteine level between subclinical hypothyroidism patients without levothyroxine treatment and healthy subjects.



**Figure 3.** Sensitivity analysis to investigate the influence of a single study on the overall meta-analysis, which compares plasma homocysteine level between subclinical hypothyroidism patients without levothyroxine treatment and healthy subjects.

26 full-text studies were excluded due to some detail reasons showed in **Figure 1**. Finally, 17 studies [4, 7-12, 14-23] were enrolled in our meta-analysis.

#### Study characteristics


The characteristics of the 17 enrolled studies are shown in **Table 1**. There were 5 case-con-

trol studies [4, 8, 9, 18, 21], 12 prospective studies [7, 10-12, 14-17, 19, 20, 22, 23]. The mean age of each group ranged from 14.9 to 57.5 years which were generally matched in healthy controls and other cases. The duration of L-T4 treatment ranged from 2 months to 18 months. The sizes of studies ranged from 14 to 164.

#### Meta-analysis of plasma Hcy levels

Firstly, we compared plasma Hcy concentrations between patients with SH without L-T4 treatment and healthy subjects, and found that plasma Hcy levels in patients with SH without L-T4 treatment were similar to that in healthy subjects [8 studies, SMD: 0.19, 95% confi-

dence interval (CI): -0.07 to 0.45,  $p=0.159$ , as shown in **Figure 2**]. Significant heterogeneity was observed among studies ( $I^2=62.9\%$ ,  $p=0.009$ ). No evidence of publication bias was noted (Begg,  $p=0.902$ ; Egger,  $p=0.858$ ). We then turn to sensitivity analysis, 1 studies [1] was excluded because it was appearing to be outliers with other studies (**Figure 3**). After



**Figure 4.** Comparison of plasma homocysteine level between overt hypothyroidism patients without levothyroxine treatment and healthy subjects.

exclusion, a meta-analysis of other 7 studies indicated that the main results remained unchanged, a significant elevation or reduction of plasma Hcy levels was not observed in patients with SH without L-T4 treatment compared with healthy subjects (SMD: 0.07, CI: -0.10 to 0.24,  $p=0.425$ ). There was no significant heterogeneity among studies ( $I^2=0.0\%$ ,  $p=0.578$ ). No evidence of publication bias was noted (Begg,  $p=0.548$ ; Egger,  $p=0.600$ ).

Next, we compared plasma Hcy concentrations between patients with OH without L-T4 treatment and healthy subjects, and found that plasma Hcy levels were significantly higher in patients with OH without L-T4 treatment than in healthy subjects (5 studies, SMD: 1.10, CI: 0.39 to 1.81,  $p=0.003$ , as shown in **Figure 4**). Significant heterogeneity was observed among studies ( $I^2=85.3\%$ ,  $p=0$ ). No evidence of publication bias was noted (Begg,  $p=0.462$ ; Egger,  $p=0.283$ ). We also use sensitivity analysis to exclude those studies that were appearing to be different from others. After excluded 1 study [4], a meta-analysis of other 4 studies indicated that the main results remained unchanged, a significant elevation of plasma Hcy levels was observed in patients with OH without L-T4 treatment compared with healthy subjects (SMD: 0.67, CI: 0.40 to 0.94,  $p=0$ ). There was no significant heterogeneity among studies ( $I^2=1.3\%$ ,

$p=0.385$ ). No evidence of publication bias was noted (Begg,  $p=1$ ; Egger,  $p=0.562$ ).


Plasma Hcy concentrations were then compared between patients with SH without L-T4 treatment and patients with OH without L-T4 treatment. Results showed that plasma Hcy levels were higher in patients with OH without L-T4 treatment than in patients with SH without L-T4 treatment (3 studies, SMD: 0.56, CI: 0.27 to 0.84,  $p=0$ , as shown in **Figure 5**). There was no significant heterogeneity among studies ( $I^2=0.0\%$ ,  $p=0.383$ ). No evidence of publication bias was noted (Begg,  $p=1$ ; Egger,  $p=0.773$ ).

Plasma Hcy levels were lower in patients with SH with L-T4 treatment than patients with SH without L-T4 treatment (9 studies, SMD: -0.18, CI: -0.32 to -0.05,  $p=0.006$ , as shown in **Figure 6**). There was no significant heterogeneity among studies ( $I^2=0.0\%$ ,  $p=0.678$ ). No evidence of publication bias was noted (Begg,  $p=0.466$ ; Egger,  $p=0.757$ ).


Finally, we compared plasma Hcy concentrations between patients with OH with L-T4 treatment and patients with OH without L-T4 treatment, and found that plasma Hcy levels were significantly lower in patients with OH with L-T4 treatment than in patients with OH without L-T4 treatment (5 studies, SMD: -1.22, CI: -1.96 to



# Homocysteine and hypothyroidism




**Figure 5.** Comparison of plasma homocysteine level between overt hypothyroidism patients without levothyroxine treatment and subclinical hypothyroidism patients without levothyroxine treatment.



**Figure 6.** Comparison of plasma homocysteine level between subclinical hypothyroidism patients with levothyroxine treatment and subclinical hypothyroidism patients without levothyroxine treatment.

-0.47,  $p=0.001$ , as shown in **Figure 7**). Significant heterogeneity was observed among studies ( $I^2=86.4\%$ ,  $p=0$ ). Begg's test ( $p=0.027$ ) and Egger's test ( $p=0.007$ ) indicated the existence of publication bias. We then used the

trim-and-fill method to adjust for funnel plot asymmetry, however, results showed no trimming performed and data unchanged. After excluded 2 studies [12, 20] by using sensitivity analysis, a meta-analysis of other 3 studies



**Figure 7.** Comparison of plasma homocysteine level between overt hypothyroidism patients with levothyroxine treatment and overt hypothyroidism patients without levothyroxine treatment.

indicated that the main results remained unchanged, a significant reduction of plasma Hcy levels was observed in patients with OH with L-T4 treatment compared with patients with OH without L-T4 treatment (SMD: -0.50, CI: -0.77 to -0.23,  $p=0$ ). There was no significant heterogeneity among studies ( $I^2=4.6\%$ ,  $p=0.351$ ). Nevertheless, Begg's test ( $p=0.296$ ) and Egger's test ( $p=0.010$ ) indicated the existence of publication bias.

## Discussion

Plasma Hcy level is affected by several genetic, physiological and life-style factors [24, 25]. The reasons for hyperhomocysteinemia are excess of dietary methionine, deficit of folate and vitamins taking part in Hcy metabolism, and deficit of kidney function [26, 27]. Kidney is a major issue for removal and metabolism of Hcy, which is closely associated with glomerular filtration rate (GFR) and albuminuria [28]. Hyperhomocysteinemia induces endothelial injury, oxidative stress, oxidation of LDL-cholesterol and smooth muscle hypertrophy [29, 30]. Toxic effect of Hcy and its spontaneous oxidation product, homocysteic acid, have the ability to activate N-methyl-D-aspartic acid (NMDA) receptors, then increase intracellular levels of calcium ion and reactive oxygen species [31, 32]. Moreover, platelet aggregation, vasomotor

function and plasma anticoagulant function are altered in the presence of elevated plasma Hcy concentrations [33]. Hyperhomocysteinemia is also one of the pathogenic factors for neuropathy, such as brain stroke and Alzheimer's disease [34]. Severe hyperhomocysteinemia can lead to convulsions and dementia [35].

Thyroid hormones strongly affect the heart and the vascular system [36]. Hypothyroidism is a common condition that is related to premature atherosclerosis and its clinical consequences, such as myocardial infarction [37]. Autopsy findings support an increase in atherosclerosis events in patients displaying hypothyroidism [38]. Several studies reported that plasma Hcy concentrations elevated in patients with OH compared with those healthy subjects [7, 39]. Consistent with these studies, the results of our meta-analysis indicated a higher plasma Hcy levels in patients with OH than in healthy subjects who have euthyroidism. The elevation of plasma Hcy level can be explained by impaired renal clearance or reduced urinary excretion in hypothyroidism [7]. The haemodynamic effects of hypothyroidism may be the reason of reduced renal blood flow and GFR [40]. Experimental studies have also implied that methylenetetrahydrofolate reductase, a key enzyme in folate metabolism, decreased in patients with hypothyroidism [39, 41]. As the

major determinant of plasma Hcystatus, folate level decreases in patients with hypothyroidism, leading to elevated plasma Hcy status.

Auer J et al demonstrated that variation of thyroid function within the normal range might affect the presence and severity of coronary atherosclerosis [42]. Taddei and his co-workers also identified a great prevalence of endothelial dysfunction in patients with SH, resulting from a reduction in NO availability [43]. However, the evidences are still judged as insufficient [44, 45]. Our meta-analysis indicated that plasma Hcy concentrations in patients with SH were similar to that in healthy subjects. This phenomenon can be interpreted as a hypothesis that slight reduction in renal function and methylenetetrahydrofolate reductase may be insufficient to influence plasma Hcy status. We also observed an elevation of plasma Hcy levels in patients with OH compared with patients with SH, which indicated that with the progression of hypothyroidism, the alteration of plasma Hcy concentrations became more and more obvious.

A randomized controlled prospective study, assessing the effect of L-T4 treatment on patients with hypothyroidism, showed a reduction in body weight, although slight, after 3 months [46]. It is also reported that L-T4 replacement decreased blood pressure and central arterial stiffness and improved endothelium-dependent vasodilatation in patients with SH [15, 47]. Moreover, a significant increase in plasma high-density lipoprotein cholesterol levels was found in patients with SH after 3 months of L-T4 treatment [48]. Another study indicated that L-T4 therapy might cause a reduction in lipoprotein (a) status in patients with OH [49]. However, a conflicting study claimed that L-T4 substitution therapy had no effect on cardiovascular risk profile in patients with hypothyroidism [10]. Besides the dose treatment duration of L-T4, hypothyroidism severity and duration may also contribute to the elevation of plasma Hcy levels. In our meta-analysis, plasma Hcy concentrations decrease after L-T4 treatment in patients with SH or OH.

Even though our meta-analysis enrolls relatively high-quality articles which shared similar characteristics, there were some limitations existing in this investigation. First, detection methods of plasma Hcy concentration varies

among enrolled studies, which may affect the accuracy of plasma Hcy concentration. Second, Clinical diversity among the studies enrolled in this meta-analysis will result in statistical heterogeneity, which may influence the outcomes, although a random effects model is used. Third, calculated Begg's and Egger's tests indicate the existence of publication bias. We are unable to obtain the original data from corresponding authors. Fourth, we need more high-quality and large-sample studies included in our meta-analysis.

Taken together, this meta-analysis suggests that the status of plasma Hcy is associated with the severity of hypothyroidism and L-T4 treatment is good for patients with hypothyroidism to reduce the plasma Hcy levels.

## Disclosure of conflict of interest

None.

**Address correspondence to:** Ying Xie, Department of Endocrinology, Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou 215004, China. Tel: +86 139 62187062; Fax: +86 512 6778 4166; E-mail: xieying182@126.com

## References

- [1] Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA and Braverman LE. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). *J Clin Endocrinol Metab* 2002; 87: 489-499.
- [2] Canturk Z, Cetinarslan B, Tarkun I, Canturk NZ, Ozden M and Duman C. Hemostatic system as a risk factor for cardiovascular disease in women with subclinical hypothyroidism. *Thyroid* 2003; 13: 971-977.
- [3] Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A and Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. *Ann Intern Med* 2000; 132: 270-278.
- [4] Bamashmoos SA, Al-Nuzaily MA, Al-Meer AM and Ali FH. Relationship between total homocysteine, total cholesterol and creatinine levels in overt hypothyroid patients. *Springerplus* 2013; 2: 423.
- [5] Veeranki S and Tyagi SC. Defective homocysteine metabolism: potential implications for skeletal muscle malfunction. *Int J Mol Sci* 2013; 14: 15074-15091.



- [6] Sadeghian S, Fallahi F, Salarifar M, Davoodi G, Mahmoodian M, Fallah N, Darvish S and Karimi A. Homocysteine, vitamin B12 and folate levels in premature coronary artery disease. *BMC Cardiovasc Disord* 2006; 6: 38.
- [7] Christ-Crain M, Meier C, Guglielmetti M, Huber PR, Riesen W, Staub JJ and Muller B. Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. *Atherosclerosis* 2003; 166: 379-386.
- [8] Turhan S, Sezer S, Erden G, Guctekin A, Ucar F, Ginis Z, Ozturk O and Bingol S. Plasma homocysteine concentrations and serum lipid profile as atherosclerotic risk factors in subclinical hypothyroidism. *Ann Saudi Med* 2008; 28: 96-101.
- [9] Luboshitzky R and Herer P. Cardiovascular risk factors in middle-aged women with subclinical hypothyroidism. *Neuro Endocrinol Lett* 2004; 25: 262-266.
- [10] Anagnostis P, Efsthadiou ZA, Slavakis A, Selalmatzidou D, Poulasouchidou M, Katergari S, Karathanasi E, Dogramatzi F and Kita M. The effect of L-thyroxine substitution on lipid profile, glucose homeostasis, inflammation and coagulation in patients with subclinical hypothyroidism. *Int J Clin Pract* 2014; 68: 857-863.
- [11] Perez A, Cubero JM, Sucunza N, Ortega E, Arceles R, Rodriguez-Espinosa J, Ordonez-Llanos J and Blanco-Vaca F. Emerging cardiovascular risk factors in subclinical hypothyroidism: lack of change after restoration of euthyroidism. *Metabolism* 2004; 53: 1512-1515.
- [12] Bicikova M, Tallova J, Hill M, Vanuga A, Putz Z and Tomandl J. Effect of treatment of hypothyroidism on the plasma concentrations of neuroactive steroids and homocysteine. *Clin Chem Lab Med* 2001; 39: 753-757.
- [13] Higgins JP, Thompson SG, Deeks JJ and Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003; 327: 557-560.
- [14] Kutluturk F, Yuce S, Tasliyurt T, Yelken BM, Aytan P, Ozturk B and Yilmaz A. Changes in metabolic and cardiovascular risk factors before and after treatment in overt hypothyroidism. *Med Glas (Zenica)* 2013; 10: 348-353.
- [15] Adrees M, Gibney J, El-Saeity N and Boran G. Effects of 18 months of L-T4 replacement in women with subclinical hypothyroidism. *Clin Endocrinol (Oxf)* 2009; 71: 298-303.
- [16] Deicher R and Vierhapper H. Homocysteine: a risk factor for cardiovascular disease in subclinical hypothyroidism? *Thyroid* 2002; 12: 733-736.
- [17] Cakal B, Cakal E, Demirbas B, Ozkaya M, Karahmetoglu S, Serter R and Aral Y. Homocysteine and fibrinogen changes with L-thyroxine in subclinical hypothyroid patients. *J Korean Med Sci* 2007; 22: 431-435.
- [18] Erdal M, Sahin M, Saglam K, Hasimi A, Uckaya G, Yarpuz MY, Taslipinar A, Gharib H and Kutlu M. Increased serum chitotriosidase activity following restoration of euthyroidism in patients with subclinical hypothyroidism. *Intern Med* 2008; 47: 1309-1314.
- [19] Ma SG, Yang LX, Bai F, Xu W and Hong B. Ischemia-modified albumin in patients with hyperthyroidism and hypothyroidism. *Eur J Intern Med* 2012; 23: e136-140.
- [20] Bicikova M, Tallova J, Stanicka S, Hill M, Vondra K and Hampl R. Levels of testosterone, allopregnanolone and homocysteine in severe hypothyroidism. *Clin Chem Lab Med* 2002; 40: 1024-1027.
- [21] Atabek ME, Pirgon O and Erkul I. Plasma homocysteine concentrations in adolescents with subclinical hypothyroidism. *J Pediatr Endocrinol Metab* 2003; 16: 1245-1248.
- [22] Beyhan Z, Erturk K, Uckaya G, Bolu E, Yaman H and Kutlu M. Restoration of euthyroidism does not improve cardiovascular risk factors in patients with subclinical hypothyroidism in the short term. *J Endocrinol Invest* 2006; 29: 505-510.
- [23] Ozcan O, Cakir E, Yaman H, Akgul EO, Erturk K, Beyhan Z, Bilgi C and Erbil MK. The effects of thyroxine replacement on the levels of serum asymmetric dimethylarginine (ADMA) and other biochemical cardiovascular risk markers in patients with subclinical hypothyroidism. *Clin Endocrinol (Oxf)* 2005; 63: 203-206.
- [24] de Bree A, Verschuren WM, Blom HJ and Kromhout D. Lifestyle factors and plasma homocysteine concentrations in a general population sample. *Am J Epidemiol* 2001; 154: 150-154.
- [25] Schneede J, Refsum H and Ueland PM. Biological and environmental determinants of plasma homocysteine. *Semin Thromb Hemost* 2000; 26: 263-279.
- [26] McNulty H, Pentieva K, Hoey L and Ward M. Homocysteine, B-vitamins and CVD. *Proc Nutr Soc* 2008; 67: 232-237.
- [27] Ruan L, Chen W, Srinivasan SR, Xu J, Toprak A and Berenson GS. Plasma homocysteine is adversely associated with glomerular filtration rate in asymptomatic black and white young adults: the Bogalusa heart study. *Eur J Epidemiol* 2009; 24: 315-319.
- [28] Soedamah-Muthu SS, Chaturvedi N, Teerlink T, Idzior-Walus B, Fuller JH and Stehouwer CD. Plasma homocysteine and microvascular and macrovascular complications in type 1 diabetes: a cross-sectional nested case-control study. *J Intern Med* 2005; 258: 450-459.
- [29] Hayden MR and Tyagi SC. Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atherosclerosis: the pleiotropic effects of folate supplementation. *Nutr J* 2004; 3: 4.

- [30] Weiss N. Mechanisms of increased vascular oxidant stress in hyperhomocysteinemia and its impact on endothelial function. *Curr Drug Metab* 2005; 6: 27-36.
- [31] Shi Q, Savage JE, Hufeisen SJ, Rauser L, Grajowska E, Ernsberger P, Wroblewski JT, Nadeau JH and Roth BL. L-homocysteine sulfonic acid and other acidic homocysteine derivatives are potent and selective metabotropic glutamate receptor agonists. *J Pharmacol Exp Ther* 2003; 305: 131-142.
- [32] Boldyrev A, Bulygina E and Makhro A. Glutamate receptors modulate oxidative stress in neuronal cells. A mini-review. *Neurotox Res* 2004; 6: 581-587.
- [33] Medina M, Urdiales JL and Amores-Sanchez MI. Roles of homocysteine in cell metabolism: old and new functions. *Eur J Biochem* 2001; 268: 3871-3882.
- [34] Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW and Wolf PA. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. *N Engl J Med* 2002; 346: 476-483.
- [35] Watkins JC and Jane DE. The glutamate story. *Br J Pharmacol* 2006; 147 Suppl 1: S100-108.
- [36] Klein I and Ojamaa K. Thyroid hormone and the cardiovascular system. *N Engl J Med* 2001; 344: 501-509.
- [37] Cappola AR and Ladenson PW. Hypothyroidism and atherosclerosis. *J Clin Endocrinol Metab* 2003; 88: 2438-2444.
- [38] Gaspar IA. Postmortem observations on the thyroid in atherosclerosis. *J Am Geriatr Soc* 1968; 16: 686-695.
- [39] Lien EA, Nedrebo BG, Varhaug JE, Nygard O, Aakvaag A and Ueland PM. Plasma total homocysteine levels during short-term iatrogenic hypothyroidism. *J Clin Endocrinol Metab* 2000; 85: 1049-1053.
- [40] Vargas F, Moreno JM, Rodriguez-Gomez I, Wangenstein R, Osuna A, Alvarez-Guerra M and Garcia-Estan J. Vascular and renal function in experimental thyroid disorders. *Eur J Endocrinol* 2006; 154: 197-212.
- [41] Morris MS, Bostom AG, Jacques PF, Selhub J and Rosenberg IH. Hyperhomocysteinemia and hypercholesterolemia associated with hypothyroidism in the third US National Health and Nutrition Examination Survey. *Atherosclerosis* 2001; 155: 195-200.
- [42] Auer J, Berent R, Weber T, Lassnig E and Eber B. Thyroid function is associated with presence and severity of coronary atherosclerosis. *Clin Cardiol* 2003; 26: 569-573.
- [43] Taddei S, Caraccio N, Virdis A, Dardano A, Versari D, Ghiadoni L, Salvetti A, Ferrannini E and Monzani F. Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. *J Clin Endocrinol Metab* 2003; 88: 3731-3737.
- [44] Helfand M. Screening for subclinical thyroid dysfunction in nonpregnant adults: a summary of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med* 2004; 140: 128-141.
- [45] Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS and Weissman NJ. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. *JAMA* 2004; 291: 228-238.
- [46] Razvi S, Ingole L, Keeka G, Oates C, McMillan C and Weaver JU. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. *J Clin Endocrinol Metab* 2007; 92: 1715-1723.
- [47] Anagnostis P, Karagiannis A, Tziomalos K, Athyros VG, Kita M and Mikhailidis DP. Endocrine hypertension: diagnosis and management of a complex clinical entity. *Curr Vasc Pharmacol* 2010; 8: 646-660.
- [48] Mutlu S, Parlak A, Aydogan U, Aydogdu A, Soykut B, Akay C, Saglam K and Taslipinar A. The effect of levothyroxine replacement therapy on lipid profile and oxidative stress parameters in patients with subclinical hypothyroid. *Arch Pharm Res* 2013; [Epub ahead of print].
- [49] Tzotzas T, Krassas GE, Konstantinidis T and Bougoulia M. Changes in lipoprotein(a) levels in overt and subclinical hypothyroidism before and during treatment. *Thyroid* 2000; 10: 803-808.